The Patent Finder

Merck Sharp & Dohme Corp.

1,737 patents currently held · Updated Nov 21, 2026
147 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 29 name spellings.

Previously recorded as Trius Therapeutics, Inc. (to 2016)

484
Ending by 2030
Nov 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 8 fees due Dec 2 to 30, 2026 · next Dec 2
  • 24 fees due Jan 2 to 28, 2027 · next Jan 2
  • 18 fees due Feb 4 to 27, 2027 · next Feb 4
  • 28 fees due Mar 1 to 29, 2027 · next Mar 1
  • 26 fees due Apr 1 to 30, 2027 · next Apr 1
  • 22 fees due May 3 to 28, 2027 · next May 3
  • 28 fees due Jun 1 to 30, 2027 · next Jun 1
  • 35 fees due Jul 5 to 30, 2027 · next Jul 5
  • 19 fees due Aug 4 to 25, 2027 · next Aug 4
  • 28 fees due Sep 1 to 30, 2027 · next Sep 1
  • 20 fees due Oct 5 to 30, 2027 · next Oct 5
  • 19 fees due Nov 3 to 17, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

  • 19 of the patents on this record were granted since Aug 23, 2026
  • 48 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,569,592Heteroaryl Substituted Pyrazole Modulators of Metabotropic Glutamate RECEPTOR-5
In force
 · High confidence
In forceHigh confidence
US 7,625,938Substituted Pyrazoles, Compositions Containing Such Compounds and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 8,486,983Self-Emulsifying Formulations of Cetp Inhibitors
In force
 · High confidence
In forceHigh confidence
US 7,528,132Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,298,543Identification and Application of Antibiotic Synergy
In force
 · High confidence
In forceHigh confidence
US 7,888,369Oxazoloisoquinoline Derivatives as Thrombin Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
US 7,547,720Ophthalmic Compositions for Treating Ocular Hypertension
In force
 · High confidence
In forceHigh confidence
US 7,709,658Process for Synthesizing a Substituted Pyrazole
In force
 · High confidence
In forceHigh confidence
US 7,834,026Spirocyclic Compounds
In force
 · High confidence
In forceHigh confidence
US 8,119,652Aryl-Fused Spirocyclic Compounds
In force
 · High confidence
In forceHigh confidence
10 of 1,737 patents shown.
Pro members see all 1,737.
Pro members: see all 1,737 patents
Also on record, not counted in the 1,737: 147 patents in force now held by others · 1,263 lapsed for an unpaid fee · 1,403 ended at full term · 6 past the fee grace period · 4 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

226 pending · 496 abandoned · 26 no status recorded

Showing 1 to 10 of 748, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
19/302,594Substituted Amino Triazolopyrimidine and Amino Triazolopyrazine Adenosine Receptor Antagonists, Pharmaceutical Compositions and Their UseAug 18, 2025Pending
19/268,323Labeling Shell for a Drug VialJul 14, 2025Pending
19/254,522Substituted Amino Triazolopyrimidine and Amino Triazolopyrazine Adenosine Receptor Antagonists, Pharmaceutical Compositions and Their UseJun 30, 2025Pending
19/250,874Antibody Neutralizing Human Respiratory Syncytial VirusJun 26, 2025Pending
19/226,799Anti-Cancer Combination Therapies Comprising CTLA-4 and PD-1 Blocking AgentsJun 3, 2025Pending
19/194,690Biomarkers for Cancer TherapeuticsApr 30, 2025Pending
19/082,466Pyridinone Derivatives as Selective Cytotoxic Agents Against Hiv Infected CellsMar 18, 2025Pending
19/080,665System for Medicinal Supply Monitoring and Management for Pooled Medicinal Product Across StudiesMar 14, 2025Pending
19/080,658System for Medicinal Supply Monitoring and Management with Controlled Packaging of Medicinal ProductMar 14, 2025Pending
19/080,640System for Medicinal Supply Monitoring and Management with Digital Display LabelingMar 14, 2025Pending
10 of 748 applications shown.
Pro members see all 748 published applications.
Pro members: see all 748 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited